Diaceutics PLC (AIM: DXRX), the diagnostic intelligence and engagement company, has announced the grant of 976,744 share options to directors and senior management under its Employee Share Option Plan, with the awards dated 23 October 2026. The options carry an exercise price of £0.002 per share, equal to the nominal value of each ordinary share. Following the grant, total options outstanding across the company stand at 7,042,578, representing approximately 8.26% of Diaceutics' current issued share capital of 85,291,958 ordinary shares. Investors in the AIM-listed company may be watching how these long-term incentive awards align executive interests with shareholder returns over the coming three-year performance period.

Key Points

  • Diaceutics PLC (AIM: DXRX) — diagnostic intelligence and engagement company operating across New York, Belfast and London
  • 976,744 share options granted on 23 October 2026 to directors and senior management under the Company's ESOP
  • Exercise price set at £0.002 per share; total options outstanding now represent approximately 8.26% of issued share capital
  • Investors should watch performance against TSR growth, revenue CAGR and Adjusted EBITDA Margin over the three-year performance period from 30 July 2026

DXRX Option Grants by Individual Director and Senior Manager

CEO Ryan Keeling received the largest allocation of 301,625 options, bringing his total shares under option to 1,640,923, equal to 1.92% of issued share capital. CFO Nick Roberts was granted 195,861 options, taking his total to 815,196 shares, or 0.96%. CCO Jordan Clark received 191,508 options for a post-grant total of 521,005 shares at 0.61%. Among PDMRs, Chris Meenan, CPTO, received 106,668 options representing 0.13% of share capital, Sandra Blake received 93,144 options at 0.30%, and CPO Susanne Munksted received 87,938 options equating to 0.48% of issued share capital.

TSR, Revenue CAGR and Adjusted EBITDA Margin Drive Executive Vesting Conditions

For executive directors Ryan Keeling, Nick Roberts and CCO Jordan Clark, vesting operates on a sliding scale up to 100% and is conditional on satisfying performance criteria based on three metrics: Total Shareholder Return growth, revenue Compound Annual Growth Rate, and Adjusted EBITDA Margin, all measured over the three-year performance period running from 30 July 2026. The Remuneration Committee will review these conditions periodically and retains discretion to amend them where appropriate, taking into account overall company performance and wider shareholder experience. For other senior employees, vesting depends on continued employment and satisfactory performance.

Diaceutics' Biopharma Client Base and Diagnostic Intelligence Model Underpin Award Rationale

Founded in 2005 and headquartered across New York, Belfast and London, Diaceutics combines diagnostic intelligence, expert insight and targeted engagement to support biopharma teams in identifying patients missed in testing and treatment pathways. The company currently works with 21 of the top 30 pharmaceutical companies globally, and states that the therapies it supports touch 1 in 10 American lives. The share option awards are described in the announcement as being made in accordance with the company's long-term incentive plan as detailed in its Annual Report, with Canaccord Genuity Limited serving as nominated adviser and broker.